Search
Pyrimethamine
go.drugbank.com/drugs/DB00205ApprovedInvestigationalVet approvedOne of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.
Fluorometholone
go.drugbank.com/drugs/DB00324ApprovedInvestigational(From Martindale, The Extra Pharmacopoeia, 30th ed, p732) … A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders.
Mixtures: FLUFORTE-N-LIQUIFILMMetaraminol
go.drugbank.com/drugs/DB00610ApprovedIt has been used primarily as a vasoconstrictor in the treatment of hypotension. … An adrenergic agonist that acts predominantly at alpha adrenergic receptors and also stimulates the release of norepinephrine.
Iobenguane sulfate I-123
go.drugbank.com/drugs/DB09546ApprovedIobenguane sulfate I-123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].
Cyclosporine
go.drugbank.com/drugs/DB00091ApprovedInvestigationalVet approved[A174049] Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Products: DNACIPOL-NHuman immunoglobulin G
go.drugbank.com/drugs/DB00028ApprovedInvestigationalIVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. … IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population.
Products: Cytotect CP Biotest 100 E/ml Infusionslösung, LIV-GAMMA SN INJDG041
go.drugbank.com/drugs/DB05027ExperimentalDG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. … It block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk.
Icotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigationalIcotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]
Levocabastine
go.drugbank.com/drugs/DB01106ApprovedLevocabastine was discovered at Janssen Pharmaceutica in 1979.
Terconazole
go.drugbank.com/drugs/DB00251Approved[A178096] Terconazole was initially approved by the FDA in 1987. … [FDA label] This drug is available in cream and suppository forms and both have demonstrated high levels of safety, efficacy, and tolerability in clinical trials.